Skip to main content

and
  1. Article

    Open Access

    Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

    Recent studies have shown that administering the aromatase inhibitor exemestane after 2–3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast can...

    G Francini, R Petrioli, A Montagnani, A Cadirni, S Campagna in British Journal of Cancer (2006)